BMS 605339
BMS 605339 is a linear tetra-peptide α-ketoamide inhibitor of HCV NS3 protease. BMS 605339 can be used in research related to hepatitis C (HCV infection).
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- CAS No.: 630417-82-2
- Formule: C35H47N5O9S
- Masse moléculaire:713.84
-
Stockage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
- Protocole
- Pureté et documentation
- Références
-
Help & FAQs
Activité biologique
Description
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| Huh-7 | CC50 |
>100 μM
Compound: 35, BMS-605339
|
Cytotoxicity against human HuH7 cells
Cytotoxicity against human HuH7 cells
|
[PMID: 24555570] |
| Huh-7 | EC50 |
12 nM
Compound: 1; BMS-605339
|
Antiviral activity against HCV genotype 1b Con1 expressing NS3 protease infected in human Huh7.5 cells assessed as reduction in viral RNA replication by luciferase reporter gene assay
Antiviral activity against HCV genotype 1b Con1 expressing NS3 protease infected in human Huh7.5 cells assessed as reduction in viral RNA replication by luciferase reporter gene assay
|
[PMID: 27564532] |
Chemical Information
-
CAS No. 630417-82-2
-
Masse moléculaire 713.84
-
Formule C35H47N5O9S
-
SMILES
O=C([C@H]1N(C[C@H](OC2=NC=CC3=C2C=CC(OC)=C3)C1)C([C@H](C(C)(C)C)NC(OC(C)(C)C)=O)=O)N[C@]4([C@H](C=C)C4)C(NS(=O)(C5CC5)=O)=O
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocole
-
Research Protocol for Infectious Diseases
Infectious-disease experiments test how pathogens interact with host barriers, innate immune receptors, inflammatory signaling, pathogen replication, and tissue injury; pattern-recognition receptors such as TLRs, RIG-I-like receptors, NOD-like receptors, and inflammasomes detect microbial molecules and activate NF-κB, interferon, and cytokine responses. The central hypothesis is that infection severity reflects the balance between pathogen burden and host response: protective inflammation restricts pathogen growth, whereas excessive or mislocalized inflammation contributes to tissue damage and disease phenotype. Unresolved questions include which host pathways are protective versus pathogenic, why some infection models fail to translate to human disease, and which combined readouts best predict clinically relevant infection outcomes.
Pureté et documentation
Références
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
BMS 605339 Related Classifications
HY-106352 Related Classifications
Powered by Bioz